They showed that CD4+ and CD8+ T cells from high-grade glioma patients (grade III n = 9; grade IV n = 7) displayed significantly higher percentage of TIM-3 positivity than CD4+ and CD8+ T cells from low-grade glioma patients (grade I n = 5; grade II n = 9) [68]. This evidence concerns the gene HAVCR2 and glioma.